AbCellera Biologics Inc. (ABCL)

NMS – Цена в реальном времени. Валюта: USD

10.35

+0.58 (5.99%)

При закрытии: Aug 12, 2026, 3:59 PM EDT

10.33

-0.02 (-0.23%)

После закрытия: Aug 12, 2026, 4:34 PM EDT

10.08.2026

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

10.08.2026

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera Biologics Inc. (NASDAQ:ABCL) announced positive top-line Phase 2 results from its Phase 1/2 trial evaluating ABCL635.

10.08.2026

AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot flashes, associated with menopause.

10.08.2026

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

New data show a single dose of AbCellera's menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.

10.08.2026

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

AbCellera ‌said Monday its experimental menopause treatment significantly reduced the frequency and severity of hot flashes in a ⁠mid-stage trial, sending its shares up 24% in premarket trading.

10.08.2026

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635.

07.08.2026

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Aug. 10, 2026.

Видео

No Data

There is no data to display

Пресс-релизы

10.08.2026

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635.

05.08.2026

AbCellera Reports Q2 2026 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q2 2026 Business Results.

AbCellera Biologics Inc. (ABCL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

Видео

No Data

Пресс-релизы

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera Reports Q2 2026 Business Results

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

Видео

No Data

Пресс-релизы

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera Reports Q2 2026 Business Results

Search stocks

AbCellera Biologics Inc. (ABCL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

Видео

No Data

Пресс-релизы

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera Reports Q2 2026 Business Results

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

Видео

No Data

Пресс-релизы

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera Reports Q2 2026 Business Results